Role of the pharmacist in reducing healthcare costs: current insights

Kieran Dalton, Stephen Byrne, Kieran Dalton, Stephen Byrne

Abstract

Global healthcare expenditure is escalating at an unsustainable rate. Money spent on medicines and managing medication-related problems continues to grow. The high prevalence of medication errors and inappropriate prescribing is a major issue within healthcare systems, and can often contribute to adverse drug events, many of which are preventable. As a result, there is a huge opportunity for pharmacists to have a significant impact on reducing healthcare costs, as they have the expertise to detect, resolve, and prevent medication errors and medication-related problems. The development of clinical pharmacy practice in recent decades has resulted in an increased number of pharmacists working in clinically advanced roles worldwide. Pharmacist-provided services and clinical interventions have been shown to reduce the risk of potential adverse drug events and improve patient outcomes, and the majority of published studies show that these pharmacist activities are cost-effective or have a good cost:benefit ratio. This review demonstrates that pharmacists can contribute to substantial healthcare savings across a variety of settings. However, there is a paucity of evidence in the literature highlighting the specific aspects of pharmacists' work which are the most effective and cost-effective. Future high-quality economic evaluations with robust methodologies and study design are required to investigate what pharmacist services have significant clinical benefits to patients and substantiate the greatest cost savings for healthcare budgets.

Keywords: clinical pharmacy; cost-effectiveness; economic evaluation; pharmaceutical care; pharmacoeconomics.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Hughes DA. From NCE to NICE: the role of pharmacoeconomics. Br J Clin Pharmacol. 2010;70(3):317–319.
    1. Lee JK, Alshehri S, Kutbi HI, Martin JR. Optimizing pharmacotherapy in elderly patients: the role of pharmacists. Integr Pharm Res Pract. 2015;4:101–111.
    1. Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14:177.
    1. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955–964.
    1. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23(1):113–132.
    1. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013;(2):CD010398.
    1. Touchette DR, Doloresco F, Suda KJ, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34(8):771–793.
    1. Perez A, Doloresco F, Hoffman JM, et al. Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2008;29(1):128.
    1. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm. 2008;65(12):1161–1172.
    1. Chisholm-Burns MA, Zivin JS, Lee JK, et al. Economic effects of pharmacists on health outcomes in the United States: a systematic review. Am J Health Syst Pharm. 2010;67(19):1624–1634.
    1. Barber N, Smith F, Anderson S. Improving quality of health care: the role of pharmacists. Qual Health Care. 1994;3(3):153–158.
    1. Hughes DA. An agenda for UK clinical pharmacology: pharmacoeconomics. Br J Clin Pharmacol. 2012;73(6):968–972.
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
    1. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445–458.
    1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19.
    1. Miguel A, Azevedo LF, Araujo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21(11):1139–1154.
    1. Hughes RG, Ortiz E. Medication errors: why they happen, and how they can be prevented. J Infus Nurs. 2005;28(2 Suppl):14–24.
    1. Bates DW, Boyle Dl, van der Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199–205.
    1. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.
    1. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–1896.
    1. Sawyer RT, Odom JM, Jennings J, Orr J, Cass AL. Discharge medication reconciliation by pharmacists to improve transitions following hospitalization (DEPTH) 2016. [Accessed December 16, 2016]. Available from: .
    1. Yarnall KS, Ostbye T, Krause KM, Pollak KI, Gradison M, Michener JL. Family physicians as team leaders: “time” to share the care. Prev Chronic Dis. 2009;6(2):A59.
    1. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616–2622.
    1. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition: multimorbidity. JAMA. 2012;307(23):2493–2494.
    1. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003) 2008;48(1):23–31.
    1. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacyled disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68(4):588–598.
    1. Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63(14):1325–1331.
    1. Mossialos E, Courtin E, Naci H, et al. From “retailers” to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy. 2015;119(5):628–639.
    1. Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract. 2007;75(3):339–347.
    1. Goble JA, Rocafort PT. Point-of-care testing: future of chronic disease state management? J Pharm Pract. 2015 Jun;:19. Epub.
    1. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001;21(11):1337–1344.
    1. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641–1647.
    1. Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy. 2011;31(7):686–694.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
    1. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15–18.
    1. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209.
    1. World Health Organization . Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: WHO; 2003.
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
    1. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(9 Suppl):S1–S24.
    1. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood) 2011;30(1):91–99.
    1. Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010) Int J Clin Pharm. 2015;37(5):687–697.
    1. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563–2571.
    1. Latif A, Pollock K, Boardman HF. The contribution of the Medicines Use Review (MUR) consultation to counseling practice in community pharmacies. Patient Educ Couns. 2011;83(3):336–344.
    1. Trueman P, Taylor DG, Lowson K, et al. Evaluation of the Scale, Causes and Costs of Waste Medicines: Final Report. York: University of York; 2010.
    1. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74(4):573–580.
    1. Food US, Administration Drug. Drug applications for over-the-counter (OTC) drugs. [Accessed October 3, 2016]. Available from: .
    1. Chui M, Stone J, Martin B, Croes K, Thorpe J. Safeguarding older adults from inappropriate over-the-counter medications: the role of community pharmacists. Gerontologist. 2014;54(6):989–1000.
    1. Schmiedl S, Rottenkolber M, Hasford J, et al. Self-medication with over-the-counter and prescribed drugs causing adverse-drug-reaction-related hospital admissions: results of a prospective, long-term multicentre study. Drug Saf. 2014;37(4):225–235.
    1. Watson M, Holland R, Ferguson J, Porteous T, Sach T, Cleland J. Community Pharmacy Management of Minor Illness (the MINA Study) London: Pharmacy Research UK; 2014.
    1. Pharmacy Ireland 2020 Working Group . Advancing Clinical Pharmacy Practice to Deliver Better Patient Care and Added Value Services: Interim Report – 2008. Dublin, Ireland: Pharmaceutical Society of Ireland; 2008.
    1. Hassell K, Noyce P, Rogers A, Harris J, Wilkinson J. A pathway to the GP: the pharmaceutical “consultation” as a first port of call in primary health care. Fam Pract. 1997;14(6):498–502.
    1. McCarthy A, O’Nolan G, Long J. Minor Ailments Schemes: An Overview of Experience up to 2015. Dublin, Ireland: Health Research Board; 2016.
    1. New Zealand Ministry of Health . Pharmacy Action Plan: 2016 to 2020. Wellington, New Zealand: Ministry of Health; 2016.
    1. Irish Pharmacy Union New pharmacy-based minor ailment scheme for medical card patients. 2016. [Accessed October 3, 2016]. Available from: .
    1. Minor ailments cost NHS £2bn/yr. Pharm J. 2008;280:109. No authors listed.
    1. Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacy assisted patient self care of minor ailments: a chronological review of UK health policy documents and key events 1997-2010. Health Policy. 2011;101(3):253–259.
    1. Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. BMJ. 2005;331(7511):271–273.
    1. Prosser LA, O’Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008;26(2):163–178.
    1. Steyer TE, Ragucci KR, Pearson WS, Mainous AG. The role of pharmacists in the delivery of influenza vaccinations. Vaccine. 2004;22(8):1001–1006.
    1. Goad JA, Taitel MS, Fensterheim LE, Cannon AE. Vaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience. Ann Fam Med. 2013;11(5):429–436.
    1. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21(16):1769–1775.
    1. Doloresco F, Vermeulen LC. Global survey of hospital pharmacy practice. Am J Health Syst Pharm. 2009;66(5 Suppl 3):S13–S19.
    1. Auta A, Maz J, Strickland-Hodge B. Perceived facilitators to change in hospital pharmacy practice in England. Int J Clin Pharm. 2015;37(6):1068–1075.
    1. Anderson S. The state of the world’s pharmacy: a portrait of the pharmacy profession. J Interprof Care. 2002;16(4):391–404.
    1. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004;24(4):427–440.
    1. Emmerton L, Marriott J, Bessell T, Nissen L, Dean L. Pharmacists and prescribing rights: review of international developments. J Pharm Pharm Sci. 2005;8(2):217–225.
    1. Gourley DR, Fitzgerald WL, Jr, Davis RL. Competency, board certification, credentialing, and specialization: who benefits? Am J Manag Care. 1997;3(5):795–801.
    1. Anderson SV, Schumock GT. Evaluation and justification of clinical pharmacy services. Expert Rev Pharmacoecon Outcomes Res. 2009;9(6):539–545.
    1. Lada P, Delgado G., Jr Documentation of pharmacists’ interventions in an emergency department and associated cost avoidance. Am J Health Syst Pharm. 2007;64(1):63–68.
    1. Papadopoulos J, Rebuck J, Lober C, et al. The critical care pharmacist: an essential intensive care practitioner. Pharmacotherapy. 2002;22(11):1484–1488.
    1. Dooley MJ, Allen KM, Doecke CJ, et al. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol. 2004;57(4):513–521.
    1. Alderman CP, Farmer C. A brief analysis of clinical pharmacy interventions undertaken in an Australian teaching hospital. J Qual Clin Pract. 2001;21(4):99–103.
    1. Spinewine A, Fialova D, Byrne S. The role of the pharmacist in optimizing pharmacotherapy in older people. Drugs Aging. 2012;29(6):495–510.
    1. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23):2483–2487.
    1. Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36(6):1101–1114.
    1. McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159(19):2306–2309.
    1. Yasunaga D, Tasaka Y, Murakami S, Tanaka A, Tanaka M, Araki H. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J Pharm Policy Pract. 2016;10:2.
    1. Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacistled medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016;6(2):e010003.
    1. Hellström LM, Bondesson A, Höglund P, Eriksson T. Errors in medication history at hospital admission: prevalence and predicting factors. BMC Clin Pharmacol. 2012;12:9.
    1. Reeder TA, Mutnick A. Pharmacist-versus physician-obtained medication histories. Am J Health Syst Pharm. 2008;65(9):857–860.
    1. Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation) J Eval Clin Pract. 2009;15(2):299–306.
    1. Ensing HT, Stuijt CC, van den Bemt BJ, et al. Identifying the optimal role for pharmacists in care transitions: a systematic review. J Manag Care Spec Pharm. 2015;21(8):614–636.
    1. Chinthammit C, Armstrong EP, Warholak TL. A cost-effectiveness evaluation of hospital discharge counseling by pharmacists. J Pharm Pract. 2012;25(2):201–208.
    1. Bondesson A, Eriksson T, Kragh A, Holmdahl L, Midlöv P, Höglund P. In-hospital medication reviews reduce unidentified drug-related problems. Eur J Clin Pharmacol. 2013;69(3):647–655.
    1. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267–270.
    1. Miller G, Franklin BD, Jacklin A. Including pharmacists on consultant-led ward rounds: a prospective non-randomised controlled trial. Clin Med. 2011;11(4):312–316.
    1. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163(17):2014–2018.
    1. Fertleman M, Barnett N, Patel T. Improving medication management for patients: the effect of a pharmacist on post-admission ward rounds. Qual Saf Health Care. 2005;14(3):207–211.
    1. Jacknin G, Nakamura T, Smally A, Ratzan R. Using pharmacists to optimize patient outcomes and costs in the ED. Am J Emerg Med. 2014;32(6):673–677.
    1. Klopotowska JE, Kuiper R, van Kan HJ, et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care. 2010;14(5):R174.
    1. de Clifford J, Caplygin F, Lam S, Leung B. Impact of an emergency department pharmacist on prescribing errors in an Australian hospital. J Pharm Pract Res. 2007;37(4):284–286.
    1. Aldridge VE, Park HK, Bounthavong M, Morreale AP. Implementing a comprehensive, 24-hour emergency department pharmacy program. Am J Health Syst Pharm. 2009;66(21):1943–1947.
    1. Wickens HJ, Farrell S, Ashiru-Oredope DA, et al. The increasing role of pharmacists in antimicrobial stewardship in English hospitals. J Antimicrob Chemother. 2013;68(11):2675–2681.
    1. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997;17(2):271–276.
    1. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients. Am J Health Syst Pharm. 2007;64(18):1935–1942.
    1. Ranchon F, Salles G, Späth HM, et al. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011;11:478.
    1. Han JM, Ah YM, Suh SY, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38(5):1124–1132.
    1. Dwyer L, Han B, Woodwell D, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8(1):63–72.
    1. Halvorsen KH, Ruths S, Granas AG, Viktil KK. Multidisciplinary intervention to identify and resolve drug-related problems in Norwegian nursing homes. Scand J Prim Health care. 2010;28(2):82–88.
    1. Hawes EM, Misita C, Burkhart JI, et al. Prescribing pharmacists in the ambulatory care setting: experience at the University of North Carolina Medical Center. Am J Health Syst Pharm. 2016;73(18):1425–1433.
    1. Erwin PB, Pitlick MK, Peters GL. Maintenance of goal blood pressure, cholesterol, and A1C levels in veterans with type 2 diabetes after discharge from a pharmacist-managed ambulatory care clinic. Diabetes Spectr. 2015;28(4):237–244.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться